SOAT1 and primary cutaneous T-cell non-Hodgkin lymphoma: Collectively, our results show how JAK/STAT pathway mutations contribute to disease progression in CTCL cells by potentiating inflammatory cytokine signaling, widening the potential therapeutic target range for this intractable entity.